Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
REMAP-CAP PLATFORM INCLUSION CRITERIA:
1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
1. Non-invasive or Invasive ventilatory support;
2. Receiving infusion of vasopressor or inotropes or both
PLATFORM EXCLUSION CRITERIA:
1. Healthcare-associated pneumonia:
1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
2. Resident of a nursing home or long term care facility
2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
3. Previous participation in this REMAP within the last 90 days
REMAP-COVID PLATFORM INCLUSION CRITERIA
1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.
REMAP-COVID PLATFORM EXCLUSION CRITERIA
1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
2. Patient is expected to be discharged from hospital today or tomorrow
3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
4. Previous participation in this REMAP within the last 90 days
DOMAIN-SPECIFIC ELIGIBLE CRITERIA:
Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
Study Location
South Health Campus
South Health CampusCalgary, Alberta
Canada
Contact Study Team
St Boniface General Hospital
St Boniface General HospitalWinnipeg, Manitoba
Canada
Contact Study Team
Ryan Zarychanski, MD
The Moncton Hospital
The Moncton HospitalFredericton, New Brunswick
Canada
Contact Study Team
Daniel Smyth, MD
Hamilton general Hospital
Hamilton general HospitalHamilton, Ontario
Canada
Contact Study Team
Alison Fox-Robichaud, MD
Grand River Hospital
Grand River HospitalKitchener, Ontario
Canada
Contact Study Team
Theresa Liu, MD
Thunder Bay General Hospital
Thunder Bay General HospitalThunder Bay, Ontario
Canada
Contact Study Team
Toronto General Hospital
Toronto General HospitalToronto, Ontario
Canada
Contact Study Team
Lorenzo del Sorbo, MD
Hospital Maisonneuve-Rosemont
Hospital Maisonneuve-RosemontMontréal, Quebec
Canada
Contact Study Team
Hopital du Sacre-Coeur de Montreal
Hopital du Sacre-Coeur de MontrealMontréal, Quebec
Canada
Contact Study Team
Martin Albert, MD
Regina General Hospital
Regina General HospitalSaskatoon, Saskatchewan
Canada
Contact Study Team
Eric Sy, MD
Rockyview General Hospital
Rockyview General HospitalCalgary, Alberta
Canada
Contact Study Team
Surrey Memorial Hospital
Surrey Memorial HospitalSurrey, British Columbia
Canada
Contact Study Team
Anish Mitra, MD
Dr. Everett Chalmers Regional Hospital
Dr. Everett Chalmers Regional HospitalFredericton, New Brunswick
Canada
Contact Study Team
Zeeshan Aslam, MD
Brantford General Hospital
Brantford General HospitalBrantford, Ontario
Canada
Contact Study Team
Brenda Reeve, MD
Kingston Health Sciences Centre
Kingston Health Sciences CentreKingston, Ontario
Canada
Contact Study Team
Niagara Health
Niagara HealthSaint Catharines, Ontario
Canada
Contact Study Team
Jennifer Tsang, MD
Mount Sinai Hospital
Mount Sinai HospitalToronto, Ontario
Canada
Contact Study Team
Sangeeta Mehta, MD
McGill University Health Centre
McGill University Health CentreMontréal, Quebec
Canada
Contact Study Team
Kosar Khwaja, MD
CIUSS Chaudieres-Appalaches (Levis)
CIUSS Chaudieres-Appalaches (Levis)Lévis, Quebec
Canada
Contact Study Team
Patrick Archambault, MD
Centre Hospitalier de l'Université de Sherbrooke
Centre Hospitalier de l'Université de SherbrookeSherbrooke, Quebec
Canada
Contact Study Team
Francois Lamontagne, MD
Foothills Medical Centre
Foothills Medical CentreCalgary, Alberta
Canada
Contact Study Team
Royal Alexandra Hospital, Alberta
Royal Alexandra Hospital, AlbertaEdmonton, Alberta
Canada
Contact Study Team
Demetrios Kutsogiannis, MD
Health Sciences Centre Winnipeg
Health Sciences Centre WinnipegWinnipeg, Manitoba
Canada
Contact Study Team
Ryan Zarychanski, MD
The Saint John General Hospital
The Saint John General HospitalFredericton, New Brunswick
Canada
Contact Study Team
Stephen Robinson, MD
Juravinski Hospital
Juravinski HospitalHamilton, Ontario
Canada
Contact Study Team
Bram Rochwerg, MD
St Mary's General Hospital
St Mary's General HospitalKitchener, Ontario
Canada
Contact Study Team
Rebecca Kruisselbrink, MD
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences CentreToronto, Ontario
Canada
Contact Study Team
Rob Fowler, MD
Toronto Western Hospital
Toronto Western HospitalToronto, Ontario
Canada
Contact Study Team
Elizabeth Wilcox, MD
Hôpital Fleury
Hôpital FleuryMontréal, Quebec
Canada
Contact Study Team
Thomas Hemmerling, MD
CHU de Québec - Université Laval
CHU de Québec - Université LavalQuébec, Quebec
Canada
Contact Study Team
Alexis Turgeon, MD
Peter Lougheed Centre
Peter Lougheed CentreCalgary, Alberta
Canada
Contact Study Team
University of Alberta Hospital
University of Alberta HospitalEdmonton, Alberta
Canada
Contact Study Team
Wendy Sligl, MD
Grace Hospital
Grace HospitalWinnipeg, Manitoba
Canada
Contact Study Team
Gloria Vazquez-Grande, MD
William Osler Health System
William Osler Health SystemBrampton, Ontario
Canada
Contact Study Team
Alexandra Binnie, MD
St. Joseph's Healthcare Hamilton
St. Joseph's Healthcare HamiltonHamilton, Ontario
Canada
Contact Study Team
Deborah Cook, MD
The Ottawa Hospital
The Ottawa HospitalOttawa, Ontario
Canada
Contact Study Team
Lauralyn McIntyre, MD
St. Michael's Hospital Unity Health Toronto
St. Michael's Hospital Unity Health TorontoToronto, Ontario
Canada
Contact Study Team
John Marshall, MD
St Joseph's Health Centre
St Joseph's Health CentreToronto, Ontario
Canada
Contact Study Team
Centre Hospitalier de l'Universite de Montreal
Centre Hospitalier de l'Universite de MontrealMontréal, Quebec
Canada
Contact Study Team
Michael Chasse, MD
IUCPQ-UL
IUCPQ-ULQuébec, Quebec
Canada
Contact Study Team
Francois Lellouche, MD
- Study Sponsored By
- UMC Utrecht
- Participants Required
- More Information
- Study ID:
NCT02735707